Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Cancer and Blood Specialists-Henderson
mi
from
Henderson, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Cancer and Blood Specialists-Henderson
mi
from
Henderson, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada - Henderson
mi
from
Henderson, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada - Henderson
mi
from
Henderson, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Las Vegas Cancer Center-Henderson
mi
from
Henderson, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Las Vegas Cancer Center-Henderson
mi
from
Henderson, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology - Henderson
mi
from
Henderson, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology - Henderson
mi
from
Henderson, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada-Southeast Henderson
mi
from
Henderson, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada-Southeast Henderson
mi
from
Henderson, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Cancer and Blood Specialists-Shadow
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Cancer and Blood Specialists-Shadow
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Nevada Cancer Research Foundation CCOP
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Nevada Cancer Research Foundation CCOP
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Radiation Oncology Centers of Nevada Central
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Radiation Oncology Centers of Nevada Central
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-San Martin
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-San Martin
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Radiation Oncology Centers of Nevada Southeast
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Radiation Oncology Centers of Nevada Southeast
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Cancer Therapy and Integrative Medicine
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Cancer Therapy and Integrative Medicine
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Cancer and Blood Specialists-Tenaya
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Cancer and Blood Specialists-Tenaya
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada - Northwest
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada - Northwest
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada-Summerlin
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada-Summerlin
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Summerlin Hospital Medical Center
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Summerlin Hospital Medical Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Las Vegas Cancer Center-Medical Center
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Las Vegas Cancer Center-Medical Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology - Fort Apache
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology - Fort Apache
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada - Central Valley
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada - Central Valley
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology - Vegas Tenaya
mi
from
Las Vegas, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology - Vegas Tenaya
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Renown Regional Medical Center
mi
from
Reno, NV
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Renown Regional Medical Center
mi
from
Reno, NV
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Portsmouth Regional Hospital
mi
from
Portsmouth, NH
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Portsmouth Regional Hospital
mi
from
Portsmouth, NH
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Hunterdon Medical Center
mi
from
Flemington, NJ
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Hunterdon Medical Center
mi
from
Flemington, NJ
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Morristown Medical Center
mi
from
Morristown, NJ
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Overlook Hospital
mi
from
Summit, NJ
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Overlook Hospital
mi
from
Summit, NJ
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Presbyterian Kaseman Hospital
mi
from
Albuquerque, NM
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Presbyterian Kaseman Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC-Albany
mi
from
Albany, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC-Albany
mi
from
Albany, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology, PC at Albany Medical Center
mi
from
Albany, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology, PC at Albany Medical Center
mi
from
Albany, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC - Amsterdam
mi
from
Amsterdam, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC - Amsterdam
mi
from
Amsterdam, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Central New York-Auburn
mi
from
Auburn, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Central New York-Auburn
mi
from
Auburn, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC - Clifton Park
mi
from
Clifton Park, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC - Clifton Park
mi
from
Clifton Park, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Mary Imogene Bassett Hospital
mi
from
Cooperstown, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Mary Imogene Bassett Hospital
mi
from
Cooperstown, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Glens Falls Hospital
mi
from
Glens Falls, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Glens Falls Hospital
mi
from
Glens Falls, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology, PC - Hudson
mi
from
Hudson, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology, PC - Hudson
mi
from
Hudson, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Central New York-Liverpool
mi
from
Liverpool, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Central New York-Liverpool
mi
from
Liverpool, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital
mi
from
Manhasset, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Orange Regional Medical Center
mi
from
Middletown, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Orange Regional Medical Center
mi
from
Middletown, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated:  12/31/1969
MidHudson Regional Hospital of Westchester Medical Center
mi
from
Poughkeepsie, NY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma
Status: Enrolling
Updated: 12/31/1969
MidHudson Regional Hospital of Westchester Medical Center
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials